Literature DB >> 9856569

Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors.

H T Kim1, B H Choi, N Niikawa, T S Lee, S I Chang.   

Abstract

Several human imprinted genes have been identified and are implicated in genetic diseases and tumorigenesis. We studied alterations of two imprinted genes, the paternally imprinted H19 and maternally imprinted IGF2, in 15 ovarian tumors with various cell types. To know allele-specific expression of the two genes, we analyzed restriction fragment length polymorphisms (RFLPs) at the 3'-untranslated region (UTR) in their cDNA, compared with those in the respective genomic DNA. As a result, biallelic H19 and IGF2 expression was observed in 8 (62%) of 13 informative (heterozygous) ovarian cancers and in 6 of 11 informative cases, respectively. H19 loss of imprinting (LOI) was most frequently observed in malignant serous cystadenocarcinoma (in four of six cases), whereas IGF2 LOI was not common in malignant epithelial cancers because three of six such LOI events occurred in benign mucinous cystadenomas and non-cancerous endometriotic cyst. Our data suggest that the alteration of H19 and IGF2 imprinting plays differential roles in tumorigenesis and progression of ovarian tumors, depending on the tissue type as well as the developmental stage. Our data may argue against tumor suppressor activity of H19 in ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856569     DOI: 10.1002/(sici)1096-8628(19981204)80:4<391::aid-ajmg16>3.0.co;2-h

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  18 in total

1.  Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.

Authors:  Celeste Leigh Pearce; Jennifer A Doherty; David J Van Den Berg; Kirsten Moysich; Chris Hsu; Kara L Cushing-Haugen; David V Conti; Susan J Ramus; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Paul D P Pharoah; Honglin Song; Susanne K Kjaer; Estrid Hogdall; Claus Hogdall; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Jacek Gronwald; Krzysztof Medrek; Anna Jakubowska; Jan Lubinski; Georgia Chenevix-Trench; Jonathan Beesley; Penelope M Webb; Andrew Berchuck; Joellen M Schildkraut; Edwin S Iversen; Patricia G Moorman; Christopher K Edlund; Daniel O Stram; Malcolm C Pike; Roberta B Ness; Mary Anne Rossing; Anna H Wu
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

2.  LncRNA H19-elevated LIN28B promotes lung cancer progression through sequestering miR-196b.

Authors:  Jin Ren; Jinling Fu; Tiangang Ma; Bingdi Yan; Rong Gao; Zhe An; Dan Wang
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

Review 3.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

4.  Intergenerational response to the endocrine disruptor vinclozolin is influenced by maternal genotype and crossing scheme.

Authors:  Edward W Pietryk; Kiristin Clement; Marwa Elnagheeb; Ryan Kuster; Kayla Kilpatrick; Michael I Love; Folami Y Ideraabdullah
Journal:  Reprod Toxicol       Date:  2018-03-10       Impact factor: 3.143

5.  IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.

Authors:  Biyun Qian; Dionyssios Katsaros; Lingeng Lu; Emilie Marion Canuto; Chiara Benedetto; Alicia Beeghly-Fadiel; Herbert Yu
Journal:  Oncol Rep       Date:  2011-01       Impact factor: 3.906

6.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

7.  The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma.

Authors:  Ling Ma; Xiaodong Tian; Feng Wang; Zhengkui Zhang; Chong Du; Xuehai Xie; Marko Kornmann; Yinmo Yang
Journal:  Cancer Biol Ther       Date:  2016-08-29       Impact factor: 4.742

8.  Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer.

Authors:  Yu-Wei Cheng; Kamran Idrees; Richard Shattock; Sajid A Khan; Zhaoshi Zeng; Cameron W Brennan; Philip Paty; Francis Barany
Journal:  Int J Cancer       Date:  2010-08-01       Impact factor: 7.396

9.  IGF-II promoter methylation and ovarian cancer prognosis.

Authors:  A C Beeghly; D Katsaros; A L Wiley; I A Rigault de la Longrais; A T Prescott; H Chen; M Puopolo; T J Rutherford; H Yu
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-14       Impact factor: 4.553

10.  Loss of imprinting of IGF2 and H19, loss of heterozygosity of IGF2R and CTCF, and Helicobacter pylori infection in laryngeal squamous cell carcinoma.

Authors:  Ivana Grbesa; Marino Marinkovic; Mirko Ivkic; Bozo Kruslin; Renata Novak-Kujundzic; Boris Pegan; Ozren Bogdanovic; Vladimir Bedekovic; Koraljka Gall-Troselj
Journal:  J Mol Med (Berl)       Date:  2008-07-05       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.